<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Blinatumomab: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Blinatumomab: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Blinatumomab: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="98582" href="/d/html/98582.html" rel="external">see "Blinatumomab: Drug information"</a> and <a class="drug drug_patient" data-topicid="98712" href="/d/html/98712.html" rel="external">see "Blinatumomab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F26595546"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Cytokine release syndrome:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving blinatumomab. Interrupt or discontinue blinatumomab and treat with corticosteroids as recommended.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neurotoxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Neurological toxicities, which may be severe, life-threatening, or fatal, occurred in patients receiving blinatumomab. Interrupt or discontinue blinatumomab as recommended.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F26714123"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Blincyto</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871850"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Blincyto</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F27254433"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Anti-CD19/CD3</span>;</li>
<li>
<span class="list-set-name">Antineoplastic Agent, Bispecific T Cell Engager</span>;</li>
<li>
<span class="list-set-name">Antineoplastic Agent, Monoclonal Antibody</span></li></ul></div>
<div class="block dop drugH1Div" id="F48879146"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9085a858-0ee5-4232-af16-2a0b5a01b0b2">Acute lymphoblastic leukemia; infant, newly diagnosed, CD19-positive B-cell precursor <i>KMT2A</i>-rearranged</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia; infant, newly diagnosed, CD19-positive B-cell precursor<i> KMT2A-</i>rearranged:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: IV: 15 mcg/<b>m<sup>2</sup></b>/day as a continuous infusion for 4 weeks beginning after completion of a 4-week induction with the Interfant 06 regimen. In the trial, patients were premedicated with dexamethasone (5 mg/<b>m<sup>2</sup></b>) administered 30 minutes prior to start of blinatumomab infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37099340']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37099340'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4e9b2fe9-c706-4329-9871-c0efe25f8a32">Acute lymphoblastic leukemia; CD19-positive B-cell precursor, MRD-positive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia; CD19-positive B-cell precursor, MRD-positive (≥0.1%):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: <b>Note:</b> Use in infants may be directed within certain investigational protocols; refer to specific protocols for additional information.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Hospitalization is recommended for the first 3 days of cycle 1 and the first 2 days of cycle 2. Close observation by a health care professional (or hospitalization) is recommended for initiation of all subsequent cycles or for therapy reinitiation (eg, treatment is interrupted for 4 or more hours). Do <b>not</b> flush infusion line, particularly when changing infusion bags or at completion of infusion; may result in overdose.</p>
<p style="text-indent:-2em;margin-left:8em;">Premedicate with dexamethasone IV 5 mg/<b>m<sup>2</sup></b> (maximum dose: 20 mg/dose) 1 hour prior to the first dose of the first cycle, or when restarting therapy after an interruption of ≥4 hours in the first cycle.</p>
<p style="text-indent:-2em;margin-left:8em;">Blinatumomab treatment course involves 1 induction cycle followed by up to 3 additional cycles for consolidation (total of up to 4 cycles).</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight &lt;45 kg: BSA-directed dosing:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Induction:</i> Cycle 1: Days 1 to 28: IV: 15 mcg/<b>m<sup>2</sup></b>/day (maximum daily dose: 28 mcg/<b>day</b>) administered as a continuous infusion followed by a 2-week treatment-free interval.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Consolidation:</i> Cycles 2 to 4: Days 1 to 28: IV: 15 mcg/<b>m<sup>2</sup></b>/day (maximum daily dose: 28 mcg/<b>day</b>) administered as a continuous infusion followed by a 2-week treatment-free interval.</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight ≥45 kg: Fixed dosing:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Induction:</i> Cycle 1: Days 1 to 28: IV: 28 mcg daily administered as a continuous infusion followed by a 2-week treatment-free interval.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Consolidation:</i> Cycles 2 to 4: Days 1 to 28: IV: 28 mcg daily administered as a continuous infusion followed by a 2-week treatment-free interval.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6a21c512-61fd-4efe-a580-3607f62b3af9">Acute lymphoblastic leukemia; CD19-positive B-cell precursor, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia; CD19-positive B-cell precursor, relapsed/refractory:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: <b>Note: </b>Hospitalization is recommended for the first 9 days of cycle 1, and the first 2 days of cycle 2. Close observation by a health care professional (or hospitalization) is recommended for initiation of all subsequent cycles or for therapy reinitiation (eg, treatment is interrupted for 4 or more hours). Do <b>not</b> flush infusion line, particularly when changing infusion bags or at completion of infusion; may result in overdose.</p>
<p style="text-indent:-2em;margin-left:6em;">Premedicate with dexamethasone IV 5 mg/<b>m<sup>2</sup></b> (maximum dose: 20 mg/dose) 1 hour prior to the first dose of the first cycle, prior to a step dose (eg, cycle 1 day 8), or when restarting therapy after an interruption of ≥4 hours in the first cycle.</p>
<p style="text-indent:-2em;margin-left:6em;">Blinatumomab treatment course involves 2 induction cycles followed by 3 additional cycles for consolidation and up to 4 additional cycles of continued therapy (total of up to 9 cycles).</p>
<p style="text-indent:-2em;margin-left:4em;">Patient weight &lt;45 kg: BSA-directed dosing:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Induction: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Cycle 1:</p>
<p style="text-indent:-2em;margin-left:10em;">Days 1 to 7: IV: 5 mcg<b>/m<sup>2</sup></b>/day (maximum daily dose: 9 mcg/<b>day</b>) administered as a continuous infusion.</p>
<p style="text-indent:-2em;margin-left:10em;">Days 8 to 28: IV: 15 mcg/<b>m<sup>2</sup></b>/day (maximum daily dose: 28 mcg/<b>day</b>) administered as a continuous infusion followed by a 2-week treatment-free interval.</p>
<p style="text-indent:-2em;margin-left:8em;">Cycle 2: Days 1 to 28: IV: 15 mcg/<b>m<sup>2</sup></b>/day (maximum daily dose: 28 mcg/<b>day</b>) administered as a continuous infusion followed by a 2-week treatment-free interval.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Consolidation:</i> Cycles 3 through 5: Days 1 to 28: IV: 15 mcg/<b>m<sup>2</sup></b>/day (maximum daily dose: 28 mcg/<b>day</b>) administered as a continuous infusion followed by a 2-week treatment-free interval.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continued therapy:</i> Cycles 6 through 9: Days 1 to 28: IV: 15 mcg/<b>m<sup>2</sup></b>/day (maximum daily dose: 28 mcg/<b>day</b>) administered as a continuous infusion followed by 8-week treatment-free interval.</p>
<p style="text-indent:-2em;margin-left:4em;">Patient weight ≥45 kg: Fixed dosing:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Induction:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Cycle 1:</p>
<p style="text-indent:-2em;margin-left:10em;">Days 1 to 7: IV: 9 mcg daily administered as a continuous infusion.</p>
<p style="text-indent:-2em;margin-left:10em;">Days 8 to 28: IV: 28 mcg daily administered as a continuous infusion followed by a 2-week treatment-free interval.</p>
<p style="text-indent:-2em;margin-left:8em;">Cycle 2: Days 1 to 28: IV: 28 mcg daily administered as a continuous infusion followed by a 2-week treatment-free interval.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Consolidation:</i> Cycles 3 through 5: Days 1 to 28: IV: 28 mcg daily administered as a continuous infusion followed by a 2-week treatment-free interval.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continued therapy:</i> Cycles 6 through 9: Days 1 to 28: IV: 28 mcg daily administered as a continuous infusion followed by an 8-week treatment-free interval.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> Infants, Children, and Adolescents: If the interruption after an adverse reaction is no longer than 7 days, continue the same cycle to a total of 28 days of infusion inclusive of the days before and after the interruption in that cycle. If an interruption due to an adverse reaction is longer than 7 days, start a new cycle.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cytokine-release syndrome (CRS):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Grade 3: Interrupt blinatumomab therapy, administer dexamethasone according to the following; and upon resolution, resume blinatumomab at the following reduced doses:</p>
<p style="text-indent:-2em;margin-left:8em;">Dexamethasone: IV, Oral:</p>
<p style="text-indent:-2em;margin-left:10em;">Patient weight &lt;45 kg: 5 mg/<b>m<sup>2</sup></b>/dose (maximum dose: 8 mg/dose) every 8 hours for up to 3 days, then taper over 4 days.</p>
<p style="text-indent:-2em;margin-left:10em;">Patient weight ≥45 kg: 8 mg/dose every 8 hours for up to 3 days, then taper over 4 days.</p>
<p style="text-indent:-2em;margin-left:8em;">Blinatumomab: After resolution, resume therapy at the following reduced doses:</p>
<p style="text-indent:-2em;margin-left:10em;">Patient weight &lt;45 kg: 5 mcg/<b>m<sup>2</sup></b>/day (maximum daily dose: 9 mcg/<b>day</b>); if after 7 days adverse reaction does not recur, further increase dose to 15 mcg/<b>m<sup>2</sup></b>/day (maximum daily dose: 28 mcg/<b>day</b>).</p>
<p style="text-indent:-2em;margin-left:10em;">Patient weight ≥45 kg: 9 mcg/day. If after 7 days adverse reaction does not recur, further increase dose to 28 mcg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 4: Discontinue blinatumomab permanently, administer dexamethasone according to the following:</p>
<p style="text-indent:-2em;margin-left:8em;">Dexamethasone: IV, Oral:</p>
<p style="text-indent:-2em;margin-left:10em;">Patient weight &lt;45 kg: 5 mg/<b>m<sup>2</sup></b>/dose (maximum dose: 8 mg/dose) every 8 hours for up to 3 days, then taper over 4 days.</p>
<p style="text-indent:-2em;margin-left:10em;">Patient weight ≥45 kg: 8 mg/dose every 8 hours for up to 3 days, then taper over 4 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neurologic toxicity:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Grade 3: Interrupt therapy for at least 3 days and until toxicity is ≤ grade 1 (mild), then resume blinatumomab dosing at 5 mcg/<b>m<sup>2</sup></b>/day if &lt;45 kg (maximum daily dose: 9 mcg/<b>day</b>) or 9 mcg/day if ≥45 kg. If after 7 days adverse reaction does not recur, further increase blinatumomab dose to 15 mcg/<b>m<sup>2</sup></b>/day if &lt;45 kg (maximum daily dose: 28 mcg/<b>day</b>) or to 28 mcg/day if ≥45 kg. If adverse reaction occurred at the 5 mcg/<b>m<sup>2</sup></b>/day dose (if &lt;45 kg) or 9 mcg daily dose, or if it takes more than 7 days to resolve, discontinue permanently.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 4: Discontinue permanently.</p>
<p style="text-indent:-2em;margin-left:6em;">Seizure: Discontinue permanently if more than 1 seizure occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Other clinically relevant toxicity:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Grade 3: Interrupt therapy until adverse reaction is ≤ grade 1 (mild), then restart blinatumomab dosing at 5 mcg/<b>m<sup>2</sup></b>/day if &lt;45 kg (maximum daily dose: 9 mcg/<b>day</b>) or 9 mcg/day if ≥45 kg. If after 7 days adverse reaction does not recur, further increase blinatumomab dose to 15 mcg/<b>m<sup>2</sup></b>/day if &lt;45 kg (maximum daily dose: 28 mcg/<b>day</b>) or to 28 mcg/<b>day</b> if ≥45 kg. If adverse reaction takes more than 14 days to resolve, discontinue permanently.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 4: Consider discontinuing permanently.</p></div>
<div class="block dorp drugH1Div" id="F51073612"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, a pharmacokinetic analysis showed that clearance values in patients with CrCl 30 to 59 mL/minute were similar to the range observed in patients with normal renal function.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51073613"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients:</p>
<p style="text-indent:-2em;margin-left:4em;">Baseline hepatic impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatotoxicity during treatment: Interrupt therapy if transaminases are &gt;5 times ULN or if bilirubin is &gt;3 times ULN.</p></div>
<div class="block doa drugH1Div" id="F26821526"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="98582" href="/d/html/98582.html" rel="external">see "Blinatumomab: Drug information"</a>)</p>
<p style="text-indent:0em;">
<b>Note:</b> Administer measures to prevent tumor lysis syndrome (eg, pretreatment nontoxic cytoreduction and hydration during treatment). Consider prophylactic antibiotics to prevent infection if appropriate; manage promptly if infection occurs.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7e53bedc-386b-4448-84e3-90eb532f17af">Acute lymphoblastic leukemia, CD19-positive B-cell precursor, minimal residual disease–positive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia, CD19-positive B-cell precursor, minimal residual disease–positive (≥0.1%):</b> Each induction or consolidation treatment cycle consists of 4 weeks of continuous infusion followed by a 2-week treatment-free interval (allow at least 2 weeks treatment-free between cycles). Therapy involves 1 induction cycle followed by up to 3 additional cycles for consolidation (total of up to 4 cycles). In the clinical study, patients could proceed to transplant at any time after cycle 1 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29358182']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29358182'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Hospitalization is recommended for the first 3 days of cycle 1, and the first 2 days of cycle 2. Close observation by a health care professional (or hospitalization) is recommended for initiation of all subsequent cycles or for therapy reinitiation (eg, treatment is interrupted for 4 or more hours). Do <b>not</b> flush infusion line, particularly when changing infusion bags or at completion of infusion; may result in overdose.</p>
<p style="text-indent:-2em;margin-left:4em;">Premedicate with the IV equivalent to prednisone 100 mg or dexamethasone 16 mg IV one hour prior to the first dose of each cycle.</p>
<p style="text-indent:-2em;margin-left:4em;">Patients ≥45 kg (fixed dose): Cycles 1 to 4: <b>IV:</b> 28 <b>mcg</b> daily administered as a continuous infusion on days 1 to 28 of a 6-week treatment cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29358182']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29358182'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Patients &lt;45 kg (dose based on BSA): Cycles 1 to 4: <b>IV:</b> 15 <b>mcg</b>/<b>m<sup>2</sup></b>/day (maximum: 28 <b>mcg</b>/day) as a continuous infusion on days 1 to 28 of a 6-week treatment cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29358182']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29358182'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b8fe3693-228b-40fd-b211-3c253d98bfd1">Acute lymphoblastic leukemia, CD19-positive B-cell precursor, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia, CD19-positive B-cell precursor, relapsed or refractory:</b> Each induction or consolidation treatment cycle consists of 4 weeks of continuous infusion followed by a 2-week treatment-free interval (allow at least 2 weeks treatment-free between cycles). Each continued therapy cycle consists of 4 weeks of continuous infusion followed by an 8-week treatment-free interval. Therapy involves up to 2 induction cycles followed by 3 additional cycles for consolidation and up to 4 additional cycles of continued therapy (total of up to 9 cycles). In clinical studies, if appropriate, patients could proceed to transplant at any time after cycle 1 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30947585','lexi-content-ref-28249141']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30947585','lexi-content-ref-28249141'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Hospitalization is recommended for the first 9 days of cycle 1, and the first 2 days of cycle 2. Close observation by a health care professional (or hospitalization) is recommended for initiation of all subsequent cycles or for therapy reinitiation (eg, treatment is interrupted for 4 or more hours). Do <b>not</b> flush infusion line, particularly when changing infusion bags or at completion of infusion; may result in overdose.</p>
<p style="text-indent:-2em;margin-left:4em;">Premedicate with dexamethasone 20 mg one hour prior to the first dose of each cycle, prior to a step dose (eg, Cycle 1 day 8), and when restarting therapy after an interruption of ≥4 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Patients ≥45 kg (fixed dose):</p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 1: <b>IV:</b> 9 <b>mcg</b> daily administered as a continuous infusion on days 1 to 7, followed by 28 <b>mcg</b> daily as a continuous infusion on days 8 to 28 of a 6-week treatment cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30947585','lexi-content-ref-28249141']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30947585','lexi-content-ref-28249141'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cycles 2 through 5: <b>IV:</b> 28 <b>mcg</b> daily administered as a continuous infusion on days 1 to 28 of a 6-week treatment cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30947585','lexi-content-ref-28249141']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30947585','lexi-content-ref-28249141'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cycles 6 through 9: <b>IV:</b> 28<b> mcg</b> daily administered as a continuous infusion on days 1 to 28 of a 12-week treatment cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30947585','lexi-content-ref-28249141']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30947585','lexi-content-ref-28249141'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Patients &lt;45 kg (dose based on BSA):</p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 1: <b>IV:</b> 5 <b>mcg</b>/<b>m<sup>2</sup></b>/day (maximum: 9 <b>mcg</b>/day) administered as a continuous infusion on days 1 to 7, followed by 15 <b>mcg</b>/<b>m<sup>2</sup></b>/day (maximum: 28 <b>mcg</b>/day) as a continuous infusion on days 8 to 28 of a 6-week treatment cycle.</p>
<p style="text-indent:-2em;margin-left:6em;">Cycles 2 through 5: <b>IV:</b> 15 <b>mcg</b>/<b>m<sup>2</sup></b>/day (maximum: 28 <b>mcg</b>/day) administered as a continuous infusion on days 1 to 28 of a 6-week treatment cycle.</p>
<p style="text-indent:-2em;margin-left:6em;">Cycles 6 through 9: <b>IV:</b> 15 <b>mcg</b>/<b>m<sup>2</sup></b>/day (maximum: 28 <b>mcg</b>/day) administered as a continuous infusion on days 1 to 28 of a 12-week treatment cycle.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991016"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, a pharmacokinetic analysis showed that clearance values in patients with CrCl 30 to 59 mL/minute were within the range observed in patients with normal kidney function.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988226"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment at baseline:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild (total bilirubin ≤ ULN and AST &gt; ULN <b>or</b> total bilirubin &gt;1 to 1.5 times ULN and any AST) or moderate (total bilirubin &gt;1.5 to 3 times ULN and any AST) impairment: There are no dosage adjustments provided in the manufacturer's labeling; however, no clinically significant difference in blinatumomab pharmacokinetics was observed based on mild or moderate hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatotoxicity during treatment: Interrupt therapy if transaminases are &gt;5 times ULN or if total bilirubin is &gt;3 times ULN.</p></div>
<div class="block adr drugH1Div" id="F26931910"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia (12% to 14%), edema (18%), hypertension (including hypertensive crisis: infants, children, adolescents: 26%; adults: 8%), hypotension (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (12% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight gain (infants, children, adolescents: 17%; adults: 6% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (infants, children, adolescents: 41%; adults: 24% to 25%; grades ≥3: 19%), decreased absolute lymphocyte count (grades 3/4: 80%), decreased serum immunoglobulins (18%; including IgA, IgG, IgM and hypogammaglobulinemia; grades ≥3: 5%), leukopenia (infants, children, adolescents: 24%; adults: 8% to 14%; grades ≥3: 7% to 9%), neutropenia (15% to 31%; grades ≥3: 15% to 28%), thrombocytopenia (infants, children, adolescents: 34%; adults: 10% to 21%; grades ≥3: 6% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (9% to 15%; including increased serum alanine aminotransferase, increased serum aspartate aminotransferase)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Cytokine release syndrome (7% to 15%), infusion-related reaction (infants, children, adolescents, and adults: 30% to 77%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (28% to 39%; bacterial infection [14%], fungal infection [10%], staphylococcal infection [≥2%], viral infection [11%]), serious infection (≤25%, including bacteremia, opportunistic infection, pneumonia, sepsis)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aphasia (12%), chills (28%), headache (23% to 39%), insomnia (18%), neurotoxicity (65%), tremor (31%; including essential tremor, intention tremor, resting tremor)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (infants, children, adolescents, and adults: 55% to 91%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Septic shock (≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Febrile neutropenia (≥2%), lymphocytopenia (≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (&lt;2%; most were neutralizing)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (10%), encephalopathy (10%), seizure (≥2%; including tonic-clonic movements)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Capillary leak syndrome, chest discomfort, chest pain, circulatory shock, flushing (including hot flash), peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic dermatitis, erythema multiforme, fixed drug eruption, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypovolemic shock</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hematologic abnormality (hematophagic histiocytosis), leukocytosis, lymphadenopathy, tumor lysis syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia, increased serum alkaline phosphatase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis and angioedema)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Systemic inflammatory response syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Altered mental status, ataxia, balance impairment, cognitive dysfunction, confusion, cranial nerve disorder (including facial nerve disorder, facial paresis, sixth nerve palsy, trigeminal nerve disorder, trigeminal neuralgia), depressed mood, depression, disorientation, disturbance in attention, drowsiness, hyperthermia, hypoesthesia, impaired consciousness, lethargy, leukoencephalopathy, memory impairment, noncardiac chest pain, pain, paresthesia, speech disturbance, stupor, suicidal ideation</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Limb pain, musculoskeletal chest pain, ostealgia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma, bronchospasm, dyspnea, dyspnea on exertion, productive cough, respiratory distress, respiratory failure (including acute respiratory failure), tachypnea, wheezing</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Gastrointestinal: Pancreatitis</p></div>
<div class="block coi drugH1Div" id="F26595549"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known hypersensitivity to blinatumomab or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F26821436"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Neutropenia and neutropenic fever, including life-threatening episodes, have been reported; neutropenia may be prolonged.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cytokine release syndrome: Cytokine release syndrome (CRS), which may be life-threatening or fatal, has occurred. CRS manifestations may include pyrexia, headache, nausea, weakness, hypotension, increased transaminases, elevated total bilirubin, and disseminated intravascular coagulation. Symptoms of infusion reactions, capillary leak syndrome, and hemophagocytic histiocytosis/macrophage activation syndrome may overlap with CRS symptoms. Advise patients to reports signs/symptoms suggestive of CRS. Administer corticosteroids for severe or life-threatening CRS. The median time to onset and resolution of CRS was 2 days (following the start of infusion) and 5 days (among cases that resolved), respectively. In one study, patients with a high tumor burden (≥50% leukemic blasts or &gt;15,000/mm<sup>3</sup> peripheral blood leukemic blast counts), or elevated lactate dehydrogenase were pretreated with dexamethasone (10 to 24 mg/m<sup>2</sup>/day for up to 5 days and concluding 3 days prior to initiating blinatumomab) to reduce the incidence of severe CRS (Topp 2015). Tocilizumab may be considered in the management of severe or life-threatening CRS associated with bi-specific T-cell engaging (BiTE) therapy (Lee 2014; Maude 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Transient increases in liver enzymes (associated both with and without CRS) may occur during therapy. In patients with acute lymphoblastic leukemia (ALL), the median time to enzyme elevation was 3 to 19 days; grade 3 or higher elevations were observed in a small percentage of patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-related infections have been reported in approximately one-fourth of patients with ALL in clinical trials (may be life-threatening or fatal). Consider prophylactic antibiotics if appropriate. Treat promptly if infection occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Leukoencephalopathy: Leukoencephalopathy (as seen on MRI) has been reported, particularly in those patients who received prior treatment with cranial irradiation and antileukemia chemotherapy (eg, high-dose methotrexate, intrathecal cytarabine).</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurotoxicity: Neurological toxicities, which may be severe, life-threatening, or fatal, have occurred. Neurotoxicity has occurred in almost two-thirds of patients with ALL in clinical trials. The median time to onset was within the first 2 weeks of therapy. Common neurological symptoms include headache and tremor (symptoms may differ in children &lt;2 years of age, and elderly patients have a higher incidence of neurotoxicity). Grade 3 or higher neurotoxicity (eg, encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders) has also been observed; other manifestations have included cranial nerve disorders. Neurotoxicity may be managed with dexamethasone (Topp 2015). Patients are at risk for loss of consciousness due to neurologic events while taking blinatumomab; advise patients to avoid driving, participating in hazardous occupations, or operating heavy or dangerous machinery during treatment. Patients with a history of (or current) clinically relevant CNS pathology were excluded from clinical trials. Advise patients to reports signs/symptoms suggestive of neurologic toxicity. The majority of symptoms resolved after interrupting therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pancreatitis: Fatal cases of pancreatitis in patients receiving blinatumomab plus dexamethasone have been reported in clinical trials and the postmarketing setting.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor lysis syndrome: Life-threatening or fatal tumor lysis syndrome (TLS) has been observed. Administer measures to prevent TLS (eg, pretreatment nontoxic cytoreduction and hydration during treatment). Signs/symptoms of TLS include acute renal failure, hyperkalemia, hypocalcemia, hyperuricemia, and/or hyperphosphatemia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concomitant drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: Vaccination with live virus vaccines is not recommended for at least 2 weeks prior to blinatumomab initiation, during treatment, and until immune system recovery following the last cycle of therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Elderly patients experienced an increased rate of neurotoxicity (including cognitive disorder), encephalopathy, confusion, and serious infections as compared to patients &lt;65 years of age.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Pediatric patients experienced an increased rate of anemia, leukopenia, thrombocytopenia, pyrexia, infusion reaction, weight gain, and hypertension as compared to adult patients. While the incidence of neurologic toxicities in patients &lt;2 years of age did not differ from other age groups, the manifestations were different; reported toxicities were agitation, headache, insomnia, somnolence, and irritability. Infants experienced an increased incidence of hypokalemia compared to adults and to older pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Diluent may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid (use preservative-free diluents if possible) or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Safety issue: Preparation and administration errors have occurred. Do not flush infusion line, particularly when changing infusion bags or at completion of infusion; may result in overdose and complications. IV bag contains overfill and volume will be more than the volume administered to the patient to account for IV line priming and to ensure that the full dose is administered. Follow preparation and administration instructions carefully. Refer to manufacturer labeling for further information.</p></div>
<div class="block dosfc drugH1Div" id="F46437844"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Provided with IV solution stabilizer to coat the prefilled NS bag prior to addition of reconstituted blinatumomab (do NOT use IV solution stabilizer for reconstitution of blinatumomab).</p></div>
<div class="block foc drugH1Div" id="F26714124"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Blincyto: 35 mcg (1 ea) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F26714122"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F26844484"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Blincyto Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">35 mcg (per each): $6,174.19</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871851"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Blincyto: 38.5 mcg (1 ea) [contains polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F52614575"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IV: <b>Note:</b> Preparation and administration errors have occurred; carefully follow administration instructions.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prior to infusion</i>: Premedication is required prior to some doses (see "Dosing: Pediatric" for further details).</p>
<p style="text-indent:-2em;margin-left:6em;">24- or 48-hour infusion: Attach the IV tubing (use only polyolefin, non-DEHP polyvinyl chloride [PVC], or ethyl vinyl acetate [EVA] tubing) to the bag with a sterile, nonpyrogenic, low protein-binding 0.2 micron in-line filter. Remove air from the IV bag. <b>Prime the IV tubing only with the prepared infusion solution</b>; do <b>not</b> prime with NS.</p>
<p style="text-indent:-2em;margin-left:6em;">7-day infusion: Attach the IV tubing (use only polyolefin, non-DEHP PVC, or EVA tubing) to the bag; an in-line filter is not required for the 7-day infusion bag. Remove air from the IV bag. <b>Prime the IV tubing only with the prepared infusion solution</b>; do <b>not</b> prime with NS.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Infusion:</i></p>
<p style="text-indent:-2em;margin-left:6em;">24- or 48-hour infusion: Administer 240 mL as a continuous IV infusion at a constant flow rate of 10 mL/hour for 24 hours or 5 mL/hour for 48 hours (depending on dose and concentration) through a dedicated lumen. Use a programmable, lockable, nonelastomeric infusion pump with an alarm. Infusion bag contains overfill (to account for tubing and priming volume). Do <b>not</b> flush infusion line, particularly when changing infusion bags or at completion of infusion; may result in excess dosage and complications. Do not infuse other medications through the same line. Discard unused infusion solution after completion of infusion.</p>
<p style="text-indent:-2em;margin-left:6em;">7-day infusion: Administer 100 mL as a continuous IV infusion at a constant flow rate of 0.6 mL/hour for 7 days through a dedicated lumen. Use a programmable, lockable, nonelastomeric infusion pump with an alarm. Do <b>not </b>use an in-line filter for the 7-day infusion bag. Infusion bag contains overfill (to account for tubing priming volume). Do <b>not</b> flush infusion line, particularly when changing infusion bags or at completion of infusion; may result in excess dosage and complications. Do not infuse other medications through the same line. Discard unused infusion solution after completion of infusion.</p></div>
<div class="block adm drugH1Div" id="F26821576"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Preparation and administration errors have occurred; carefully follow administration instructions.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>24- or 48-hour infusion:</i> Administer 240 mL as a continuous IV infusion at a constant flow rate of 10 mL/hour for 24 hours or 5 mL/hour for 48 hours (depending on dose, duration, and/or concentration) through a dedicated lumen. Use a programmable, lockable, non-elastomeric infusion pump with an alarm. IV tubing should include a sterile, nonpyrogenic, low protein-binding, 0.2 micron in-line filter.</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:0em;">
<i>7-day infusion</i>
<i>: </i>Administer 100 mL as a continuous IV infusion at a constant flow rate of 0.6 mL/hour for 7 days through a dedicated lumen. Use a programmable, lockable, non-elastomeric infusion pump with an alarm. Do <b>not</b> use an in-line filter for the 7-day infusion bag.</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:0em;">Only use polyolefin, non-di-ethylhexylphthalate (DEHP) PVC, or ethyl vinyl acetate infusion bags, pump cassettes, and IV tubing. IV tubing should be primed with final prepared solution for infusion and not with NS. Premedication is required prior to some doses (see Dosing: Adult for further details).</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:0em;">Infusion bag contains overfill (to account for tubing priming volume). Discard unused infusion solution after completion of infusion. Do <b>not</b> flush infusion line, particularly when changing infusion bags or at completion of infusion; may result in excess dosage and complications. Do not infuse other medications through the same line.</p></div>
<div class="block sts drugH1Div" id="F26821449"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials (drug and solution stabilizer) in the original package at 2°C to 8°C (36°F to 46°F); do not freeze. Protect from light. Intact vials of both drug and stabilizer may be stored for a maximum of 8 hours at 23°C to 27°C (73°F to 81°F) in the original carton to protect from light. Reconstituted solution in the vial is stable for up to 4 hours at 23°C to 27°C (73°F to 81°F) or up to 24 hours at 2°C to 8°C (36°F to 46°F). If not used immediately, solutions diluted for infusion should be refrigerated. Solutions diluted for infusion <b>(preservative free) </b>are stable in NS for up to 48 hours at 23°C to 27°C (73°F to 81°F) or up to 8 days at 2°C to 8°C (36°F to 46°F). Solutions diluted for infusion <b>(with preservative)</b> are stable in NS for up to 7 days at 23°C to 27°C (73°F to 81°F) or up to 14 days at 2°C to 8°C (36°F to 46°F). Infusion should be completed within these time frames; if IV bag of solution for infusion is not administered within the time frames and temperatures indicated, discard; do not refrigerate again. Follow USP 797 recommendations for beyond use dates based on the level of risk for preparation.</p></div>
<div class="block meg drugH1Div" id="F26619135"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Blincyto: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F125557s023s026lbl.pdf%23page%3D41&amp;token=0bGLUZ8QCAdIC3g1FbEqdUY6WhFr%2Fr4Ga2aH58cvSEBSerklhSyIwVUY%2FZZWLSEUZP6%2BoeG2zjAVcq3hYjggFOxeRX9U%2F4R6pKG7344ncf9VlTWUo7%2FT7I86lBzQzDvb&amp;TOPIC_ID=113708" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125557s023s026lbl.pdf#page=41</a></p></div>
<div class="block usep drugH1Div" id="F53571185"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) (FDA approved in pediatric patients [age not specified] and adults); treatment of CD-19 positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) ≥0.1% (FDA approved in pediatric patients [age not specified] and adults). <b>Note:</b> FDA approval for this indication is through an accelerated process; continued approval is dependent on verification of clinical benefit in further trials. Has also been used for treatment of <i>KMT2A</i>-rearranged CD19-positive B-cell precursor infant ALL.</p></div>
<div class="block mst drugH1Div" id="F26821363"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-4em;margin-left:6em;">Blinatumomab may be confused with bezlotoxumab, obinutuzumab.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Preparation and administration errors have occurred. Do not flush infusion line, particularly when changing infusion bags or at completion of infusion; may result in overdose and complications. IV bag contains overfill and volume will be more than the volume administered to the patient to account for IV line priming and to ensure that the full dose is administered. Carefully follow preparation and administration instructions. Refer to manufacturer labeling for further information.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F26639712"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F26639709"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Busulfan: Blinatumomab may increase the serum concentration of Busulfan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49095589"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Verify pregnancy status prior to initiating treatment in patients who could become pregnant. Patients who could become pregnant should use effective contraception during treatment and for 48 hours after the last blinatumomab dose.</p></div>
<div class="block pri drugH1Div" id="F26821445"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on the mechanism of action, in utero exposure to blinatumomab may cause fetal harm. Pregnancy may be compromised due to activation of the maternal immune system. In addition, newborns exposed to blinatumomab in utero may develop B-cell lymphocytopenia; monitor B-lymphocytes prior to administering live virus vaccines.</p></div>
<div class="block mopp drugH1Div" id="F53571184"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential and liver function tests (ALT, AST, gamma-glutamyltransferase, and total bilirubin) (baseline and throughout therapy); signs/symptoms of cytokine-release syndrome, infusion reactions, neurotoxicity, infection, pancreatitis, and tumor lysis syndrome.</p></div>
<div class="block pha drugH1Div" id="F26821503"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Blinatumomab is a bispecific T-cell engager (BiTE) which binds to CD19 expressed on B-cells and CD3 expressed on T-cells. It activates endogenous T cells by connecting CD3 in the T-cell receptor complex with CD19 on B-cells (malignant and benign), thus forming a cytolytic synapse between a cytotoxic T-cell and the cancer target B-cell (Topp 2014). Blinatumomab mediates the production of cytolytic proteins, release of inflammatory cytokines, and proliferation of T cells, which result in lysis of CD19-positive cells.</p></div>
<div class="block phk drugH1Div" id="F26821505"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Pediatric patients &lt;18 years of age: 3.14 ± 2.97 L/m<sup>2</sup>; Adults: 5.27 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Degraded into small peptides and amino acids via catabolic pathways.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Pediatric patients &lt;18 years of age: 2.04 ± 1.35 hours; Adults: 2.2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (negligible amounts).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Mean systemic clearance: Adults: 3.1 L/hour.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F49189360"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Blincyto</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin<i>. J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/blinatumomab-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/blinatumomab-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Blincyto.2">
<a name="Blincyto.2"></a>Blincyto (blinatumomab) [prescribing information]. Thousand Oaks, CA: Amgen Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/blinatumomab-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/blinatumomab-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30947585">
<a name="30947585"></a>Dombret H, Topp MS, Schuh AC, et al. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. <i>Leuk Lymphoma</i>. 2019;60(9):2214-2222. doi:10.1080/10428194.2019.1576872<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/blinatumomab-pediatric-drug-information/abstract-text/30947585/pubmed" id="30947585" target="_blank">30947585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29358182">
<a name="29358182"></a>Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. <i>Blood.</i> 2018;131(14):1522-1531. doi:10.1182/blood-2017-08-798322<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/blinatumomab-pediatric-drug-information/abstract-text/29358182/pubmed" id="29358182" target="_blank">29358182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/blinatumomab-pediatric-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/blinatumomab-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/blinatumomab-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/blinatumomab-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28249141">
<a name="28249141"></a>Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. <i>N Engl J Med</i>. 2017;376(9):836-847. doi: 10.1056/NEJMoa1609783.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/blinatumomab-pediatric-drug-information/abstract-text/28249141/pubmed" id="28249141" target="_blank">28249141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24876563">
<a name="24876563"></a>Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. <i>Blood.</i> 2014;124(2):188-195. doi:10.1182/blood-2014-05-552729<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/blinatumomab-pediatric-drug-information/abstract-text/24876563/pubmed" id="24876563" target="_blank">24876563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24876563">
<a name="24876563"></a>Litzow MR, Zhuoxin S, Paietta E, et al. Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with B-lineage acute lymphoblastic leukemia in measurable residual disease negative remission: results from the ECOG-ACRIN E1910 randomized phase III national cooperative clinical trials network trial. <i>Blood.</i> 2022;140(2):1-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/blinatumomab-pediatric-drug-information/abstract-text/24876563/pubmed" id="24876563" target="_blank">24876563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/blinatumomab-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24667956">
<a name="24667956"></a>Maude SL, Barrett D, Teachey DT, et al. Managing cytokine release syndrome associated with novel T cell-engaging therapies. <i>Cancer J</i>. 2014;20(2):119-122. doi:10.1097/PPO.0000000000000035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/blinatumomab-pediatric-drug-information/abstract-text/24667956/pubmed" id="24667956" target="_blank">24667956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/blinatumomab-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25524800">
<a name="25524800"></a>Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study [published correction appears in <i>Lancet Oncol</i>. 2015;16(4):e158]. <i>Lancet Oncol</i>. 2015;16(1):57-66.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/blinatumomab-pediatric-drug-information/abstract-text/25524800/pubmed" id="25524800" target="_blank">25524800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25385737">
<a name="25385737"></a>Topp MS, Gokbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. <i>J Clin Oncol</i>. 2014;32(36):4134-4140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/blinatumomab-pediatric-drug-information/abstract-text/25385737/pubmed" id="25385737" target="_blank">25385737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23024237">
<a name="23024237"></a>Topp MS, Gokbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. <i>Blood</i>. 2012;120(26):5185-5187.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/blinatumomab-pediatric-drug-information/abstract-text/23024237/pubmed" id="23024237" target="_blank">23024237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21576633">
<a name="21576633"></a>Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. <i>J Clin Oncol</i>. 2011;29(18):2493-2498.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/blinatumomab-pediatric-drug-information/abstract-text/21576633/pubmed" id="21576633" target="_blank">21576633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37099340">
<a name="37099340"></a>van der Sluis IM, de Lorenzo P, Kotecha RS, et al. Blinatumomab added to chemotherapy in infant lymphoblastic leukemia. <i>N Engl J Med</i>. 2023;388(17):1572-1581. doi:10.1056/NEJMoa2214171<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/blinatumomab-pediatric-drug-information/abstract-text/37099340/pubmed" id="37099340" target="_blank">37099340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27998223">
<a name="27998223"></a>von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>J Clin Oncol</i>. 2016;34(36):4381-4389.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/blinatumomab-pediatric-drug-information/abstract-text/27998223/pubmed" id="27998223" target="_blank">27998223</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 113708 Version 147.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
